Mast_Group.svg

New Approved CLSI Criteria for Bovine Mastitis Pathogens

11 Oct 2022
Susan Thomson
Susan Thomson
International Business Manager
test@mast-group.com
test@linkedin.com
New Approved CLSI Criteria for Bovine Mastitis Pathogens

Reliable and accurate susceptibility testing of mastitis pathogens to the Kanamycin–Cefalexin 30–15 µg combination is now more accessible for veterinary practitioners. This Kanamycin–Cefalexin combination, marketed as Ubrolexin® by Boehringer Ingelheim, offers a broadened spectrum of activity and is indicated for the treatment of mastitis in lactating dairy cows.

The Clinical and Laboratory Standards Institute (CLSI) Subcommittee for Veterinary Antimicrobial Susceptibility Testing (VAST) has recently approved interpretive criteria for this combination for disc diffusion susceptibility testing. These criteria are essential for guiding appropriate treatment selection and helping to prevent antimicrobial resistance.

Mast Group Ltd currently supplies the CFX15/K30C/NCE combination disc, featuring:

  • Supplied in cartridge format – 5 × 50 disc packs

  • Compatibility with the MAST® DISCMASTER Dispenser

  • Seamless integration into routine laboratory workflows

  • Full compliance with CLSI VAST standards

ShareContact us